Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer-Reference-Cited by-同舟云学术

Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer

Published:2020-08 Issue:7 Volume:49 Page:e63-e65
ISSN:1536-4828
Container-title:Pancreas
language:en
Short-container-title:Pancreas

Author:

Iede Kiyotsugu,Yamada Terumasa,Kato Ryo,Ueda Masami,Tsuda Yujiro,Nakashima Shinsuke,Ohta Katsuya,Matsuyama Jin,Ikenaga Masakazu,Tominaga Shusei

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference5 articles.

1. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;N Engl J Med,2013

2. Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer;Cancer Rep,2020

3. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer;Br J Cancer,2016

4. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer;Oncologist,2015

5. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial;J Natl Cancer Inst,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Significance of Increased Skeletal Muscle Mass During Nab-Paclitaxel Plus Gemcitabine Treatment in Patients With Advanced Pancreatic Cancer;Pancreas;2023-12-28

2. Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer;Medicine;2022-07-22

3. Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer;Pancreas;2022-03

4. Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan;Pancreas;2022-01

5. High Rate of Pancreatic Structural Changes Among Tobacco-Using Individuals at High Risk for Pancreatic Ductal Adenocarcinoma Undergoing Endoscopic Ultrasound;Pancreas;2022-01